GSK Plc won’t submit an experimental rheumatoid arthritis therapy to regulators after disappointing clinical trial results.
One study for the medicine, a monoclonal antibody called otilimab, failed to meet its goal. While another two did succeed, GSK said Thursday that “the efficacy demonstrated is unlikely to transform patient care.”
